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OBJECTIVES:With rapid ageing, prevalence of dementia in the elderly is increasing
at a fast rate. This study aimed to examine themedical expenditure for dementia in
the elderly and to analyze factors affecting its expenditure in South Korea.
METHODS:We analyzed the data of sampled patients from National Health Insur-
ance. Direct medical costs including hospitalization, out-patient service and phar-
macy costs were calculated from claims of patients in 2010. To examine the deter-
minants of costs, we used a two-part model to deal with the zero values of
expenditure. The first part predicted the probability of any expenditure with a
logistic regression while the second part used an OLS regression model with log-
transformed expenditure. RESULTS: Average medical expenditure in the total of
3729 dementia patients was 5.6 million won. Average expenditure increased with
severity (p0.004). In the first part, patients in the long-term care facilities had a
lower probability of expensing medical costs than patients with family-based care
(OR0.30, 95% CI 0.21-0.43). The probability of incurring expenditure was much
higher for severe patients thanmild patients (OR1.33, 95% CI 1.02-1.74). Among
the patients with expenditure, better educated (elementary, middle school gradu-
ates and high school graduates) spent more costs than under educated (less than
elementary graduates) patients (17%, 27%, respectively) (p0.05). Cost estimates
demonstrated that education levels, facility care and types of dementia were sig-
nificantly associated with the costs. Interestingly, the costs were 20% lower for
severe patients versus mild patients because outpatient and pharmacy costs de-
creased as the severity increases. CONCLUSIONS: This study showed a burden of
medical expenditure for dementia and associations between various factors and
costs. Costs were significantly different among conditions. However, this study
considered only medical costs for dementia. Therefore, further research needs to
include non-medical costs and indirect costs for dementia.
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OBJECTIVES: To review the consequences associated with schizophrenia relapse.
METHODS:We searched the Medline, EBSCO and EMBASE up to February 2012 for
eligible studies. Included studies were systematic reviews, meta-analyses, pro-
spective observational studies, retrospective cohort studies or randomized con-
trolled trials (RCTs) measuring the cost consequences of schizophrenia relapse or
recurrence. The consequences from studies with different designs, countries and
years were compared. RESULTS: Eleven studies conducted in Europe, United
States, Germany, England, Australia, Japan and Brazil were identified and re-
viewed. Relapse in schizophrenia were characterized by higher rates of hospital-
ization, day hospital visit and psychiatric visit; longer inpatient days and more
medications. Schizophrenia patients with relapse incurred significantly higher to-
tal annual direct medical costs, which were almost 2 to 4 times of those without
relapse. The absolute annual cost of relapsed schizophrenia patients changed tre-
mendously in different countries, approximately ranging from 1,198 USD (in 2006
USD) in Brazil to 50,986 USD (in 2000 USD) in the United States. The average cost of
a relapse was 3421 EUR (in 2005 EUR). The driving part of the cost difference was
attributed to inpatient care. Higher frequencies of reemergence of psychotic symp-
toms and aggravation of positive or negative symptoms were observed in these
studies. Significant differences in patient quality of life in favor of patients without
relapsewere captured in some of the studies, while in other studies the differences
were insignificant. The most frequently employed quality of life measurements
were PANSS, CGI, GAF, Lehman QoL, EQ-5D, MLDL GI and SF-36. CONCLUSIONS:
The findings of the review confirmed the significant economic burden of schizo-
phrenia relapse, and showed such costs were mainly driven by more hospitaliza-
tions and longer duration of hospitalization. The cost consequence of relapse var-
ies among countries. Relapse causes deterioration in patient quality of life as well.
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OBJECTIVES:To analyze the cost consequences associatedwith non-compliance in
schizophrenia treatment.METHODS:We searched the Pubmed, EBSCO, Adis Phar-
macoEconomics, Wiley, Springer and Elsevier up to February 2012 for eligible stud-
ies using the key words of schizophrenia, compliance, adherence and cost. In-
cluded studies were systematic reviews, meta-analyses, prospective observational
studies and retrospective cohort studies measuring the cost consequences related
to non-compliance of anti-psychotic medication. The cost consequences from dif-
ferent studies were compared. RESULTS: Six primary studies and seven literature
reviews were identified and included in this analysis, of the primary studies 2 in
UK, 1 in Sweden, 1 in Canada and 1 in Taiwan. Non-compliance with treatment is
the main driver of relapses and re-hospitalizations which cause significant eco-
nomic burden to patients and their families. Schizophrenia patients who were not
compliant with treatment hadmore relapses, higher rates of hospitalizations, lon-
ger hospitalization days,more needs for intensive care,more psychiatric visits, and
more medications. One of the UK studies showed that non-compliant patients
incurred significantly higher total annual direct medical costs, which were almost
1.5 times of those who were compliant with treatment. The other 5-year UK study
showed that if we improve compliance rate for a patient by 20%, £16,147 will be
saved and 0.55 relapse will be avoided for the patient. Three studies showed a
significant increase of compliance by using long-acting Risperidone injection com-
pared with oral anti-psychotics and long-acting typical anti-psychotic injections
which may result in cost savings and improvement in patient quality of life.
CONCLUSIONS: The findings of the review showed significant cost saving by in-
creasing compliance with treatment due to reductions in relapse and re-hospital-
ization. Long-acting Risperidone injection can significant increase the compliance
of medication which may result in cost savings.
PMH10
COST-EFFECTIVENESS OF ANTIDEPRESSANT BASED ON DISCRETE EVENT
SIMULATION MODELING IN TREATMENT OF MAJOR DEPRESSIVE EPISODES: A
COMPARISON OF AGOMELATINE VERSUS ESCITALOPRAM-VENLAFAXINE
Sughondhabirom A1, Chamchitchun S2
1King Chulalongkorn Memorial Hospital, Department of Psychiatry, Faculty of Medicine,
Chulalongkorn University, Bangkok, Thailand, 2Srithanya Psychiatric Hospital, Nonthaburi,
Thailand
OBJECTIVES: To compare cost-effectiveness of Agomelatine versus Escitalopram-
Venlafaxine matrix comparator in terms of Life Year in Remission (LYR) and Qual-
ity Adjusted Life Year (QALY).METHODS: A discrete event simulation hypothetical
model was developed to describe the course of depressive disorders treatment in
Thai setting. A sample size of 250,000 depressed patients and 1,000 simulations
were generated. Antidepressants were analysed for treatment of acute phase
(12-24 weeks), continuation phase (6-9 months) and maintenance phase (over 2
years of follow-up). Model was based on real Thai data, which acquired from public
data, including disease parameters, costs of antidepressants, costs of medication
treatments for insomnia and sexual side-effects, costs of cognitive behavioral
therapy(CBT) and electroconvulsive therapy(ECT), mean costs of psychiatric visits
and mortality data. Impact measures were derived from a systematic review and
meta-analysis of international literature. Willingness to pay was set at 300,000
THB/QALY. Results were presented as costs (Thai Baht currency) per QALY and per
LYR averted, compared to thematrix comparator which contained 41.8% venlafax-
ine-treated and 58.2% escitalopram-treated in real Thai data. Model simulation
initiated with either Agomelatine 25 mg or a Matrix comparator (80% with Escita-
lopram 10mg, 20% with Escitalopram 20mg 20% or Venlafaxine150 mg). Relapse
cases need treatment assumed addition of Sertraline, CBT and ECT. RESULTS: The
IncrementalCost-EffectivenessRatios (ICER)ofAgomelatine forepisodic treatmenteither
with or without a continuation of maintenance phase at base case was more effective
than thematrix comparator by177,008THB per LYR and100,767THB per QALY. Prob-
abilistic sensitivity analysis supported thatAgomelatinewasmore cost effective than the
matrix comparator at probability above 0.75. CONCLUSIONS: In Thai setting, Agomala-
tinewasamorecost-effective treatmentoption fordepressivedisordersascompared toa
matrix comparator of EscitalopramandVenlafaxine.
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OBJECTIVES: To evaluate the cost-effectiveness of Risperidone long-acting injec-
tion (LAI) in schizophrenia treatment. METHODS: We searched medical literature
using key words risperidone, long-acting, cost-effectiveness, pharmacoeconomics
and economic evaluation in Medline, Embase, Elsevier and Ovid databases up to
January 2012. Literature review studies were excluded from this review. RESULTS:
Twelve primary study articles were indentified and included in this review of
which 2 in Germany, 2 in Sweden, 1 in US, 1 in France, 1 in Belgium, 1 in the UK, 1
in New Zealand, 1 in Canada, 1 in China Mainland, 1 in Taiwan. All studies only
calculated the direct costs of treatments, including hospitalizations, medications,
and consultations. Ten studies showed cost savings while the rest 2 studies con-
cluded Risperidone LAI was more cost-effective than comparators. Among the 10
studies showing cost savings, 4 studies further demonstrated better efficacy of
Risperidone LAI than oral psychotics and Haloperidol long-acting injection, 4 stud-
ies showed a range of 0.22-0.55 relapses reduction with Risperidone LAI treatment
resulting in significant cost savings, 2 studies showed a 0.043-0.103 QALY gained
per patient in 5 years with Risperidone LAI, 3 studies compared the inpatient days
and hospitalization frequencies before and after using Risperidone LAI with fewer
inpatient days and hospitalizations after Risperidone LAI treatment. Among the 2
studies showing Risperidone LAI wasmore cost-effective, the study in ChinaMain-
land showed Risperidone LAI was more cost-effective than Olanzopine and Que-
tiepine while the study from Taiwan found Risperidone LAI was more cost-effec-
tive than Olanzopine and depot haloperidol. CONCLUSIONS: Based on the
available studies, this systematic review found that Risperidone LAI was a cost-
effective treatment for schizophrenia patients.
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OBJECTIVES: Schizophrenia has been found to be associated with poor medication
adherence, and a higher prevalence of diabetes. As appropriate adherence to hy-
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